Correlation Between Sino Biopharmaceutica and Lixte Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sino Biopharmaceutica and Lixte Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sino Biopharmaceutica and Lixte Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sino Biopharmaceutical Ltd and Lixte Biotechnology Holdings, you can compare the effects of market volatilities on Sino Biopharmaceutica and Lixte Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sino Biopharmaceutica with a short position of Lixte Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sino Biopharmaceutica and Lixte Biotechnology.

Diversification Opportunities for Sino Biopharmaceutica and Lixte Biotechnology

-0.09
  Correlation Coefficient

Good diversification

The 3 months correlation between Sino and Lixte is -0.09. Overlapping area represents the amount of risk that can be diversified away by holding Sino Biopharmaceutical Ltd and Lixte Biotechnology Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lixte Biotechnology and Sino Biopharmaceutica is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sino Biopharmaceutical Ltd are associated (or correlated) with Lixte Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lixte Biotechnology has no effect on the direction of Sino Biopharmaceutica i.e., Sino Biopharmaceutica and Lixte Biotechnology go up and down completely randomly.

Pair Corralation between Sino Biopharmaceutica and Lixte Biotechnology

Assuming the 90 days horizon Sino Biopharmaceutica is expected to generate 1.03 times less return on investment than Lixte Biotechnology. But when comparing it to its historical volatility, Sino Biopharmaceutical Ltd is 3.52 times less risky than Lixte Biotechnology. It trades about 0.08 of its potential returns per unit of risk. Lixte Biotechnology Holdings is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  200.00  in Lixte Biotechnology Holdings on September 12, 2024 and sell it today you would lose (16.00) from holding Lixte Biotechnology Holdings or give up 8.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Sino Biopharmaceutical Ltd  vs.  Lixte Biotechnology Holdings

 Performance 
       Timeline  
Sino Biopharmaceutical 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Sino Biopharmaceutical Ltd are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain primary indicators, Sino Biopharmaceutica showed solid returns over the last few months and may actually be approaching a breakup point.
Lixte Biotechnology 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Lixte Biotechnology Holdings are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Lixte Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point.

Sino Biopharmaceutica and Lixte Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sino Biopharmaceutica and Lixte Biotechnology

The main advantage of trading using opposite Sino Biopharmaceutica and Lixte Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sino Biopharmaceutica position performs unexpectedly, Lixte Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lixte Biotechnology will offset losses from the drop in Lixte Biotechnology's long position.
The idea behind Sino Biopharmaceutical Ltd and Lixte Biotechnology Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities